Therapy: rituximab and PML risk-informed decisions needed!
Leonard H
LH
Calabrese
Eamonn S
ES
Molloy
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived; D002983:Clinical Competence; D003657:Decision Making; D020000:Decision Support Systems, Clinical; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000009:adverse effects* / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000276:immunology / Q000517:prevention & control; D009894:Opportunistic Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*; D018570:Risk Assessment; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab